Current emerging and investigational drugs for the treatment of chronic hand eczema

References

• Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015 Jan;13(1):e1–22.
   PubMed Web of Science ®Google Scholar
• Johannisson A, Pontén A, Svensson Å. Prevalence, incidence and predictive factors for hand eczema in young adults - a follow-up study. BMC Dermatol. 2013 Oct 29;13:14.
   PubMedGoogle Scholar
• Thyssen JP, Johansen JD, Linneberg A, et al. The epidemiology of hand eczema in the general population–prevalence and main findings. Contact Dermatitis. 2010 Feb;62(2):75–87.
   PubMed Web of Science ®Google Scholar
• Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and severity of hand eczema in the Dutch general population: a cross-sectional, questionnaire study within the lifelines cohort study. Acta Derm Venereol. 2022 Jan 5;102:adv00626.
   PubMedGoogle Scholar
• Veien NK, Hattel T, Laurberg G. Hand eczema: causes, course, and prognosis II. Contact Dermatitis. 2008 Jun;58(6):335–339.
   PubMedGoogle Scholar
• Lee GR, Maarouf M, Hendricks AK, et al. Current and emerging therapies for hand eczema. Dermatol Ther. 2019 May;32(3):e12840.
   PubMed Web of Science ®Google Scholar
• Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol JEADV. 2020 Jan;34(Suppl 1):4–12.
   PubMedGoogle Scholar
• Agner T, Andersen KE, Brandao FM, et al. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis. 2008 Jul;59(1):43–47.
   PubMed Web of Science ®Google Scholar
• Cvetkovski RS, Zachariae R, Jensen H, et al. Quality of life and depression in a population of occupational hand eczema patients. Contact Dermatitis. 2006 Feb;54(2):106–111.
   PubMedGoogle Scholar
• Cvetkovski RS, Rothman KJ, Olsen J, et al. Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. Br J Dermatol. 2005 Jan;152(1):93–98.
   PubMedGoogle Scholar
• Diepgen TL, Scheidt R, Weisshaar E, et al. Cost of illness from occupational hand eczema in Germany. Contact Dermatitis. 2013 Aug;69(2):99–106.
   PubMedGoogle Scholar
• Coenraads PJ. Hand eczema. N Engl J Med. 2012 Nov 8;367(19):1829–1837.
   PubMed Web of Science ®Google Scholar
• Veien NK, Hattel T, Laurberg G. Hand eczema: causes, course, and prognosis I. Contact Dermatitis. 2008 Jun;58(6):330–334.
   PubMedGoogle Scholar
• Agner T, Aalto-Korte K, Andersen KE, et al. Classification of hand eczema. J Eur Acad Dermatol Venereol JEADV. 2015 Dec;29(12):2417–2422.
   PubMedGoogle Scholar
• Leonard A, Guttman-Yassky E. The unique molecular signatures of contact dermatitis and implications for treatment. Clin Rev Allergy Immunol. 2019 Feb;56(1):1–8.
   PubMed Web of Science ®Google Scholar
• Dhingra N, Shemer A, Correa da Rosa J, et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol. 2014 Aug;134(2):362–372.
   PubMed Web of Science ®Google Scholar
• Ruff SMD, Engebretsen KA, Zachariae C, et al. The association between atopic dermatitis and hand eczema: a systematic review and meta-analysis. Br J Dermatol. 2018 Apr;178(4):879–888.
   PubMedGoogle Scholar
• William A, Lisa CS. Atopic profiles, familial histories, and coexisting conditions associated with hand eczema. Skinmed. 2005 Jul-Aug;4(4):204–210.
   PubMedGoogle Scholar
• Coenraads PJ, Diepgen TL. Risk for hand eczema in employees with past or present atopic dermatitis. Int Arch Occup Environ Health. 1998 Feb;71(1):7–13.
   PubMedGoogle Scholar
• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016 Mar 12;387(10023):1109–1122.
   PubMed Web of Science ®Google Scholar
• Sanyal RD, Pavel AB, Glickman J, et al. Atopic dermatitis in African American patients is T(H)2/T(H)22-skewed with T(H)1/T(H)17 attenuation. Ann Allergy Asthma Immunol. 2019 Jan;122(1):99–110.e6.
   PubMed Web of Science ®Google Scholar
• Suárez-Fariñas M, Ungar B, Correa da Rosa J, et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol. 2015 May;135(5):1218–1227.
   PubMed Web of Science ®Google Scholar
• Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015 Jun;73(2):311–318.
   PubMed Web of Science ®Google Scholar
• Suárez-Fariñas M, Tintle SJ, Shemer A, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011 Apr;127(4):954–64.e1–4.
   Google Scholar
• De Benedetto A, Rafaels NM, McGirt LY, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011 Mar;127(3):773–86.e1–7.
   Google Scholar
• Gittler JK, Krueger JG, Guttman-Yassky E. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol. 2013 Feb;131(2):300–313.
   PubMed Web of Science ®Google Scholar
• Szalus K, Trzeciak M, Nowicki RJ. JAK-STAT inhibitors in atopic dermatitis from pathogenesis to clinical trials results. Microorganisms. 2020 Nov 6;8(11):1743.
   PubMed Web of Science ®Google Scholar
• Wang X, Ye L, Lai Q, et al. Altered epidermal permeability barrier function in the uninvolved skin supports a role of epidermal dysfunction in the pathogenesis of occupational hand eczema. Skin Pharmacol Physiol. 2020;33(2):94–101.
   PubMedGoogle Scholar
• Molin S, Merl J, Dietrich KA, et al. The hand eczema proteome: imbalance of epidermal barrier proteins. Br J Dermatol. 2015 Apr;172(4):994–1001.
   PubMedGoogle Scholar
• Tauber M, Bérard E, Lourari S, et al. Latent class analysis categorizes chronic hand eczema patients according to skin barrier impairment. J Eur Acad Dermatol Venereol JEADV. 2020 Jul;34(7):1529–1535.
   PubMedGoogle Scholar
• Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges. Ther Clin Risk Manag. 2020;16:1319–1332.
   PubMed Web of Science ®Google Scholar
• de León FJ, Berbegal L, Silvestre JF. Management of Chronic Hand Eczema. Actas Dermosifiliogr. 2015 Sep;106(7):533–544.
   PubMedGoogle Scholar
• Elsner P, Agner T. Hand eczema: treatment. J Eur Acad Dermatol Venereol JEADV. 2020 Jan;34(Suppl 1):13–21.
   PubMed Web of Science ®Google Scholar
• Kircik LH, Tropmann C. Treatment of mild-to-moderate chronic hand dermatitis with clobetasol propionate 0.05% EF foam: results from an open-label study. J Drugs Dermatol. 2011 Dec;10(12):1398–1402.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br J Dermatol. 1995 May;132(5):675–682.
   PubMed Web of Science ®Google Scholar
• Egawa K. Topical vitamin D3 derivatives in treating hyperkeratotic palmoplantar eczema: a report of five patients. J Dermatol. 2005 May;32(5):381–386.
   PubMedGoogle Scholar
• Yang M, Chang JM. Successful treatment of refractory chronic hand eczema with calcipotriol/betamethasone ointment: a report of three cases. Exp Ther Med. 2015 Nov;10(5):1943–1946.
   PubMedGoogle Scholar
• Juntongjin P, Pongprasert R. Calcipotriol ointment shows comparable efficacy to topical steroids in chronic hand eczema. Dermatol Ther. 2019 Jul;32(4):e12956.
   PubMedGoogle Scholar
• Belsito DV, Fowler JF Jr., Marks JG Jr., et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis. 2004 Jan;73(1):31–38.
   PubMed Web of Science ®Google Scholar
• Hordinsky M, Fleischer A, Rivers JK, et al. Efficacy and safety of pimecrolimus cream 1% in mild-to-moderate chronic hand dermatitis: a randomized, double-blind trial. Dermatology. 2010 Aug;221(1):71–77.
   PubMedGoogle Scholar
• Schliemann S, Kelterer D, Bauer A, et al. Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis. 2008 May;58(5):299–306.
   PubMedGoogle Scholar
• Thelmo MC, Lang W, Brooke E, et al. An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema. J Dermatolog Treat. 2003 Sep;14(3):136–140.
   PubMedGoogle Scholar
• Bissonnette R, Pavel AB, Diaz A, et al. Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol. 2019 Nov;144(5):1274–1289.
   PubMed Web of Science ®Google Scholar
• Kahn JS, Grossman-Kranseler JS, Zancanaro P, et al. Topical Crisaborole in the treatment of atopic hand dermatitis: a retrospective chart review. Dermatitis. 2021 Nov-Dec 01;32(6):e141–e143.
   PubMedGoogle Scholar
• Blair HA, Scott LJ. Alitretinoin: a review in severe chronic hand eczema. Drugs. 2016 Sep;76(13):1271–1279.
   PubMed Web of Science ®Google Scholar
• Nada HR, Rashed LA, Elantably DMM, et al. Expression of retinoid receptors in hand eczema. Int J Dermatol. 2020 May;59(5):576–581.
   PubMedGoogle Scholar
• Sarkar R, Chugh S, Garg VK. Acitretin in dermatology. Indian J Dermatol Venereol Leprol. 2013 Nov-Dec;79(6):759–771.
   PubMed Web of Science ®Google Scholar
• Schindler M, Drozdenko G, Kühl AA, et al. Immunomodulation in patients with chronic hand eczema treated with oral alitretinoin. Int Arch Allergy Immunol. 2014;165(1):18–26.
   PubMed Web of Science ®Google Scholar
• Diepgen TL, Pfarr E, Zimmermann T. Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients. Acta Derm Venereol. 2012 May;92(3):251–255.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Worm M, Gerlach B, et al. Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. Br J Dermatol. 2010 Feb 1;162(2):420–426.
   PubMedGoogle Scholar
• Fowler JF, Graff O, Hamedani AG. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. J Drugs Dermatol. 2014 Oct;13(10):1198–1204.
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008 Apr;158(4):808–817.
   PubMed Web of Science ®Google Scholar
• Luchsinger I, Vogler T, Schwieger-Briel A, et al. Safe and effective use of alitretinoin in children with recalcitrant hand eczema and other dermatoses - a retrospective analysis. J Eur Acad Dermatol Venereol JEADV. 2020 May;34(5):1037–1042.
   PubMed Web of Science ®Google Scholar
• Dirschka T, Reich K, Bissonnette R, et al. An open-label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids. Clin Exp Dermatol. 2011 Mar;36(2):149–154.
   PubMed Web of Science ®Google Scholar
• Morris M, Schifano L, Fong R, et al. Safety of alitretinoin for severe refractory chronic hand eczema: clinical studies and postmarketing surveillance. J Dermatolog Treat. 2016;27(1):54–58.
   PubMed Web of Science ®Google Scholar
• Politiek K, Christoffers WA, Coenraads PJ, et al. Alitretinoin and Acitretin in severe chronic hand eczema; results from a retrospective daily practice study. Dermatol Ther. 2016 Sep;29(5):364–371.
   PubMed Web of Science ®Google Scholar
• Tan J, Maari C, Nigen S, et al. Open-label exploratory study of Acitretin for the treatment of severe chronic hand dermatitis. J Dermatolog Treat. 2015;26(4):373–375.
   PubMed Web of Science ®Google Scholar
• Thestrup-Pedersen K, Andersen KE, Menné T, et al. Treatment of hyperkeratotic dermatitis of the palms (eczema keratoticum) with oral Acitretin. A single-blind placebo-controlled study. Acta Derm Venereol. 2001 Oct-Nov;81(5):353–355.
   PubMedGoogle Scholar
• Song M, Lee HJ, Lee WK, et al. Acitretin as a therapeutic option for chronic hand eczema. Ann Dermatol. 2017 Jun;29(3):385–387.
   PubMedGoogle Scholar
• Christoffers WA, Politiek K, Coenraads PJ, et al. Drug survival of cyclosporine in the treatment of hand eczema: a multicentre, daily use study. J Eur Acad Dermatol Venereol JEADV. 2016 Jan;30(1):63–66.
   PubMedGoogle Scholar
• Alitretinoin vs Cyclosporine in severe recurrent vesicular hand eczema. Available from: https://ClinicalTrials.gov/show/NCT03026946
   Google Scholar
• Agarwal US, Besarwal RK. Topical clobetasol propionate 0.05% cream alone and in combination with azathioprine in patients with chronic hand eczema: an observer blinded randomized comparative trial. Indian J Dermatol Venereol Leprol. 2013 Jan-Feb;79(1):101–103.
   PubMedGoogle Scholar
• Oosterhaven JA, Politiek K, Schuttelaar MA. Azathioprine treatment and drug survival in patients with chronic hand eczema - results from daily practice. Contact Dermatitis. 2017 May;76(5):304–307.
   PubMedGoogle Scholar
• Egan CA, Rallis TM, Meadows KP, et al. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol. 1999 Apr;40(4):612–614.
   PubMed Web of Science ®Google Scholar
• Shaffrali FC, Colver GB, Messenger AG, et al. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol. 2003 Mar;48(3):417–419.
   PubMed Web of Science ®Google Scholar
• O’Shea PM, Lugo-Somolinos A. Methotrexate versus Acitretin in the treatment of chronic hand dermatitis. J Drugs Dermatol. 2015 Dec;14(12):1389–1391.
   PubMedGoogle Scholar
• Politiek K, van der Schaft J, Christoffers WA, et al. Drug survival of methotrexate treatment in hand eczema patients: results from a retrospective daily practice study. J Eur Acad Dermatol Venereol JEADV. 2016 Aug;30(8):1405–1407.
   PubMed Web of Science ®Google Scholar
• Ghosh N, Nasrin T, Mahmud H, et al. Efficacy and safety of low dose Methotrexate in the treatment of chronic hand eczema. J Pak Assoc Dermatol. 2020;30(1):3–8.
   Google Scholar
• Abrouk M, Farahnik B, Zhu TH, et al. Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. J Am Acad Dermatol. 2017 Jul;77(1):177–180.
   PubMedGoogle Scholar
• Navarro-Triviño FJ, Cuenca-Barrales C, Vega-Castillo JJ, et al. Chronic hand eczema and hepatogenic pruritus with good response to apremilast. Dermatol Ther. 2019 May;32(3):e12879.
   PubMedGoogle Scholar
• Pincelli C, Schafer PH, French LE, et al. Mechanisms underlying the clinical effects of apremilast for psoriasis. J Drugs Dermatol. 2018 Aug 1;17(8):835–840.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013 Aug;12(8):888–897.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008 May;24(5):1529–1538.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Krueger JG. New therapies for psoriasis and psoriatic arthritis. Curr Opin Rheumatol. 2016 May;28(3):204–210.
   PubMed Web of Science ®Google Scholar
• Garcet S, Nograles K, Correa da Rosa J, et al. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. J Allergy Clin Immunol. 2018 Sep;142(3):1010–1013.e6.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Imafuku S, Poulin Y, et al. A Phase 2 randomized trial of apremilast in patients with atopic dermatitis. J Invest Dermatol. 2019 May;139(5):1063–1072.
   PubMed Web of Science ®Google Scholar
• Apremilast and moderate to severe chronic hand dermatitis. Available from: https://ClinicalTrials.gov/show/NCT03741933
   Google Scholar
• Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009 Mar;228(1):273–287.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol. 2009 Apr;10(4):356–360.
   PubMed Web of Science ®Google Scholar
• He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019 Apr;20(2):181–192.
   PubMed Web of Science ®Google Scholar
• Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015 Jan;64(1):41–51.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Delgocitinib: first approval. Drugs. 2020 Apr;80(6):609–615.
   PubMed Web of Science ®Google Scholar
• Worm M, Bauer A, Elsner P, et al. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol. 2020 May;182(5):1103–1110.
   PubMed Web of Science ®Google Scholar
• Phase 2b dose-ranging trial to evaluate Delgocitinib cream 1, 3, 8, and 20 mg/g compared to Delgocitinib cream vehicle over a 16-week treatment period in adult subjects with chronic hand eczema. Available from: https://ClinicalTrials.gov/show/NCT03683719.
   Google Scholar
• Hand eczema: Pan-JAK inhibitor Delgocitinib shows dose-dependent response in Phase 2b trial. [ press release]. [Internet]. Medscape; 2020.
   Google Scholar
• Efficacy and safety of Delgocitinib cream in adults with moderate to severe chronic hand eczema. Available from: https://ClinicalTrials.gov/show/NCT04871711
   Google Scholar
• Efficacy and safety of Delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 2). Available from: https://ClinicalTrials.gov/show/NCT04872101
   Google Scholar
• Open-label multi-site extension trial in subjects who completed the DELTA 1 or DELTA 2 trials. Available from: https://ClinicalTrials.gov/show/NCT04949841
   Google Scholar
• Kontzias A, Kotlyar A, Laurence A, et al. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 2012 Aug;12(4):464–470.
   PubMed Web of Science ®Google Scholar
• Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021 Oct;85(4):863–872.
   PubMed Web of Science ®Google Scholar
• Topical Ruxolitinib evaluation in chronic hand eczema study 1. Available from: https://ClinicalTrials.gov/show/NCT05219864
   Google Scholar
• Topical Ruxolitinib evaluation in chronic hand eczema study 2. Available from: https://ClinicalTrials.gov/show/NCT05233410
   Google Scholar
• Card GL, England BP, Suzuki Y, et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure. 2004 Dec;12(12):2233–2247.
   PubMed Web of Science ®Google Scholar
• Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014 May 16;20(5):22608.
   PubMedGoogle Scholar
• Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048.
   PubMed Web of Science ®Google Scholar
• Peter D, Jin SL, Conti M, et al. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol. 2007 Apr 15;178(8):4820–4831.
   PubMedGoogle Scholar
• Dong C, Virtucio C, Zemska O, et al. Treatment of skin inflammation with Benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes. J Pharmacol Exp Ther. 2016 Sep;358(3):413–422.
   PubMed Web of Science ®Google Scholar
• Bäumer W, Hoppmann J, Rundfeldt C, et al. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17–26.
   PubMedGoogle Scholar
• Guttman-Yassky E, Hanifin JM, Boguniewicz M, et al. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2019 Jan;28(1):3–10.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996 Jul;107(1):51–56.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang J, Zhang X, et al. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2019 May 1;155(5):585–593.
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema. Available from: https://ClinicalTrials.gov/show/NCT04378569.
   Google Scholar
• Nedoszytko B, Sokołowska-Wojdyło M, Ruckemann-Dziurdzińska K, et al. Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis. Postepy Dermatol Alergol. 2014 May;31(2):84–91.
   PubMed Web of Science ®Google Scholar
• Ouwehand K, Scheper RJ, de Gruijl TD, et al. Epidermis-to-dermis migration of immature Langerhans cells upon topical irritant exposure is dependent on CCL2 and CCL5. Eur J Immunol. 2010 Jul;40(7):2026–2034.
   PubMedGoogle Scholar
• Pastore S, Mascia F, Girolomoni G. The contribution of keratinocytes to the pathogenesis of atopic dermatitis. Eur J Dermatol. 2006 Mar-Apr;16(2):125–131.
   PubMed Web of Science ®Google Scholar
• A study for a topical medication versus Placebo in patients with hand dermatitis. Available from: https://ClinicalTrials.gov/show/NCT03703895.
   Google Scholar
• Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019 Jan;143(1):155–172.
   PubMed Web of Science ®Google Scholar
• Wang FP, Tang XJ, Wei CQ, et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2018 May;90(2):190–198.
   PubMed Web of Science ®Google Scholar
• Oosterhaven JAF, Romeijn GLE, Schuttelaar MLA. Dupilumab treatment of very severe refractory atopic hand eczema. JAMA Dermatol. 2018 Aug 1;154(8):969–970.
   PubMed Web of Science ®Google Scholar
• Zirwas MJ. Dupilumab for hand eczema. J Am Acad Dermatol. 2018 Jul;79(1):167–169.
   PubMed Web of Science ®Google Scholar
• Lee N, Chipalkatti N, Zancanaro P, et al. A retrospective review of dupilumab for hand dermatitis. Dermatology. 2019;235(3):187–188.
   PubMed Web of Science ®Google Scholar
• Oosterhaven JAF, Voorberg AN, Romeijn GLE, et al. Effect of dupilumab on hand eczema in patients with atopic dermatitis: an observational study. J Dermatol. 2019 Aug;46(8):680–685.
   PubMed Web of Science ®Google Scholar
• Voorberg AN, Romeijn GLE, de Bruin-Weller MS, et al. The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay registry. Contact Dermatitis. 2022 Mar 13. DOI:https://doi.org/10.1111/cod.14104.
   Google Scholar
• Efficacy and safety of Dupilumab chronic hands eczema refractory to highly potent topical corticosteroids. Available from: https://ClinicalTrials.gov/show/NCT03861455.
   Google Scholar
• Dupilumab in severe chronic hand eczema. Available from: https://ClinicalTrials.gov/show/NCT04512339.
   Google Scholar
• Wu NL, Huang DY, Tsou HN, et al. Syk mediates IL-17-induced CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6. J Invest Dermatol. 2015 Feb;135(2):490–498.
   PubMedGoogle Scholar
• Wu N-L, Huang D-Y, Wang L-F, et al. Spleen tyrosine kinase mediates EGFR signaling to regulate keratinocyte terminal differentiation. J Invest Dermatol. 2016;136(1):192–201.
   PubMed Web of Science ®Google Scholar
• Pavel AB, Song T, Kim HJ, et al. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. J Allergy Clin Immunol. 2019 Oct;144(4):1011–1024.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Maari C, Forman S, et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol. 2019 Oct;181(4):733–742.
   PubMed Web of Science ®Google Scholar
• Study to evaluate ASN002 in subjects with moderate to severe chronic hand eczema. Available from: https://ClinicalTrials.gov/show/NCT03728504
   Google Scholar
• Asana biosciences announces positive topline results from phase 2b study of oral JAK/SYK inhibitor gusacitinib (ASN002) in patients with chronic hand eczema: rapid and significant improvement demonstrated [ press release]. [Internet]. Business Wire; 2020
   Google Scholar
• Asana BioSciences’ gusacitinib granted FDA Fast-Track designation for moderate-to-severe chronic hand eczema. [ press release]. [Internet]. Business Wire; 2021
   Google Scholar
• Frings VG, Böer-Auer A, Breuer K. Histomorphology and immunophenotype of Eczematous skin lesions revisited-skin biopsies are not reliable in differentiating allergic contact dermatitis, irritant contact dermatitis, and atopic dermatitis. Am J Dermatopathol. 2018 Jan;40(1):7–16.
   PubMedGoogle Scholar